BioGenes, specialists in ELISA development, production and host cell protein (HCP) assay development, announced the establishment of a Scientific Advisory Board, which includes the following four renowned experts:
- Professor Hans Henning von Horsten, Industrial Biomanufacturing, HTW-Berlin University of Applied Sciences, Berlin
- Professor Frank F. Bier, Deptartment Biosystems Integration and Process Automatisation, Fraunhofer IZI-BB, Potsdam-Golm
- Dr Wieland Wolf, CEO ProBioGen AG, Berlin
- Dr Jens Knauer, Method Development Virology Testing Quality Control, IDT Biologika GmbH, Dessau-Rosslau
The Scientific Advisory Board will provide BioGenes with significant expertise and experience throughout the whole drug development and manufacturing value chain to help strengthen and extend the company’s position in the field of quality control for biopharmaceuticals.
Dr Alexander Knoll, Managing Director of BioGenes, said: “We are pleased to welcome these renowned experts to BioGenes’ Scientific Advisory Board. Creating the SAB represents another important step forward for the company. Its members bring a wealth of experience in the area of biomanufacturing and analytics and will provide crucial advice based on their specialisations which will be essential to guide us in prioritising and driving forward our goals.”
Professor Hans Henning von Horsten is co-inventor of several patents and pending patent applications for the biomanufacturing business. He was among the key inventors of ProBioGen’s GlymaxX antibody engineering technology that was out licensed to Boehringer-Ingelheim, Novartis, Thermo-Fisher Scientific and several other drug developers.
Hans Henning von Horsten is also head of the Working Group Biotechnology at the Berlin-Brandenburg branch of the VDI Association of German Engineers.
Professor Frank F. Bier is the founder of the Molecular Bioanalytics branch of the Fraunhofer Institute for Biomedical Engineering (Fraunhofer IBMT). In 2003, he was appointed Chair of Applied Bioelectronics and Biochip Technology at the University of Potsdam. Since 2014 he has been the head of the Department Biosystems Integration and Process Automatisation of the newly formed branch Fraunhofer Institute for Cell Therapy and Immunology, Biotechnology and Bioproduction (Fraunhofer IZI-BB) in Potsdam-Golm, Germany.
Dr Wieland Wolf is the CEO of ProBioGen, an internationally operating contract development and manufacturing organisation (CDMO). He has three decades of experience in the biopharmaceutical industry.
Wolf was involved in pioneering product registrations at Bioferon, headed a production unit for API and parenteral dosage forms at the same company, and was responsible for the biotechnology division of the Rentschler Group, which he led through its transformation from a product-oriented enterprise into an established service provider and contract manufacturing organisation (CMO).
Wolf is the President of the European Association for Pharma Biotechnology and a member of the Board of Trustees of the Fraunhofer Institute for Interfacial Engineering and Biotechnology (Fraunhofer IGB) in Stuttgart, Germany.
Dr Jens Knauer has a strong background in GLP/GMP contract research, method development and as a Principal Investigator in several clinical trials. Before joining IDT Biologika, he was involved in the development and validation of immunological assays at the Fraunhofer Institute for Cell Therapy and Immunology where he was also instrumental in building a GLP laboratory for immuno-toxicological assays.
